Table 2.

Study and patient characteristics of included studies

Study	Publication year	Nation	Capacity (Cancer/all)	Age (Years)	PSA (Mean/range)	Gleason score (Median/range)
Kumar et al.	2007	India	23/60	64.5	11.04/0.48–1,000	NA
Aydin et al.	2012	Turkey	40/45	69	70.6/1.6–139.53	7/5–10
Koo et al.	2013	Korea	80/80	66	7.16/1.24–56.98	7/6–9
Ibrahiem et al.	2012	Egypt	68/92	65.3	26.3/NA	≥7
Kim et al.	2010	Korea	48/48	66	7.21/2.3–23.2	7/6–9
Yamamura et al.	2011	Germany	21/50	61.8	7.19/NA	7.13/5–10
Girometti et al.	2012	Italy	5/26	64	5.95/2.52–9.74	6.8/6–9
Selnæs et al.	2012	Norway	36/48	62.2	9.8/4.0–21.4	7.3/6–9
Portalez et al.	2010	France	28/68	62.4	9.16/1.6–25	NA
Tamada et al.	2011	Japan	35/50	70	6.84/4.06–9.94	7/6–10
Rinaldi et al.	2012	Italy	36/41	69	15.15/5.98–133	NA
Yagci et al.	2011	Turkey	21/43	66	9.1/1.4–120	7/6–10
Weidner et al.	2011	Germany	10/16	63.5	NA/4.25–137	NA/6–8
Kim et al.	2007	Korea	35/35	64.3	7.94/1.32–35.3	7/6–8
Chen et al.	2008	China	15/42	63	11.93/4.7–147	<7
Iwazawa et al.	2011	Japan	72/178	68.8	20.51/4.04–568.5	7.04
Miao et al.	2007	Japan	34/37	63.7	22.4/4.07–136	NA
Isebaert et al.	2013	Belgium	75/75	66	10.4/1.5–70.9	7/6–10
Vilanova et al.	2011	Spain	38/70	63.5	7.4/4–17.2	7/5–8
Peng et al.	2013	America	48/48	62.5	7.0/0.8–256	7/6–9
Lim et al.	2009	South Korea	52/52	65	10.5/1.2–79.6	7/6–9

PSA prostate-specific antigen (ng/mL), NA data unavailable